Sign In
Last checked at 
21 May 2026 07:00
IXICO plc
("IXICO", the "Company" or the "Group")
Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million
21 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug and diagnostics development in neurological disorders, today announced a contract win and contract extension with a total value of £1.3 million over 2 years.
Blood based biomarker validation contract
IXICO will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease (AD) blood-based biomarker test for a global diagnostics and life sciences company with the aim of facilitating FDA regulatory clearance.
Phase 2 contract extension
This extends an existing Phase 2 Huntington's Disease (HD) clinical trial contract with a leading global pharmaceutical company, expanding the existing analysis methodologies with three additional analysis approaches.
Bram Goorden, Chief Executive Officer of IXICO, commented: "These latest contract wins are first and foremost important for progress in research and patient care. They also fit squarely in the growth strategy for our company, hitting three key components of the plan: deepening impact in broader CNS areas such as AD while maintaining leadership in rare neurodegenerative disease areas like HD, enabling novel modalities and moving toward high-value later stage clinical development work. It is deeply satisfying to see an increasing number of clients recognise IXICO's leading role in the field of CNS precision medicine".
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Ends
For further information please contact:
IXICO plc | +44 (0) 20 3763 7499 |
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer | |
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.
Follow the stocks
